Invesco Biotechnology & Genome ETF (PBE)
Assets | $257.46M |
Expense Ratio | 0.58% |
PE Ratio | 17.03 |
Shares Out | 3.97M |
Dividend (ttm) | $0.03 |
Dividend Yield | 0.05% |
Ex-Dividend Date | Jun 24, 2024 |
Payout Ratio | 0.86% |
1-Year Return | +5.31% |
Volume | 8,163 |
Open | 64.48 |
Previous Close | 64.80 |
Day's Range | 64.23 - 64.58 |
52-Week Low | 52.47 |
52-Week High | 67.76 |
Beta | 0.92 |
Holdings | 32 |
Inception Date | Jun 23, 2005 |
About PBE
Fund Home PageThe Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering. PBE was launched on Jun 23, 2005 and is issued by Invesco.
Top 10 Holdings
47.58% of assetsName | Symbol | Weight |
---|---|---|
BioMarin Pharmaceutical Inc. | BMRN | 5.39% |
Regeneron Pharmaceuticals, Inc. | REGN | 5.27% |
Gilead Sciences, Inc. | GILD | 5.23% |
Incyte Corporation | INCY | 5.16% |
Vertex Pharmaceuticals Incorporated | VRTX | 5.11% |
Amgen Inc. | AMGN | 5.07% |
Illumina, Inc. | ILMN | 4.97% |
Neurocrine Biosciences, Inc. | NBIX | 4.78% |
Ionis Pharmaceuticals, Inc. | IONS | 3.37% |
Halozyme Therapeutics, Inc. | HALO | 3.23% |
Dividends
Ex-Dividend | Amount | Pay Date |
---|---|---|
Jun 24, 2024 | $0.0082 | Jun 28, 2024 |
Mar 18, 2024 | $0.02419 | Mar 22, 2024 |
Jun 20, 2023 | $0.01407 | Jun 23, 2023 |
Mar 23, 2020 | $0.02898 | Mar 31, 2020 |
Sep 24, 2018 | $0.00207 | Sep 28, 2018 |
Jun 16, 2017 | $0.21532 | Jun 30, 2017 |
News
![](https://cdn.snapi.dev/images/v1/m/o/laboratory-2815640-1920-1-0.jpg)
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
![](https://cdn.snapi.dev/images/v1/b/i/biotech-pharma-lab-shutterstock-203454226-3eec378fd51648b69233f4f9b139072d.jpg)
2 Biotech Funds Poised for a Healthy Breakout
Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.
![](https://cdn.snapi.dev/images/v1/l/a/lab-217041-1280-29.jpg)
3 Health Care ETFs Where Components Are Enduring Downgrades
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
![](https://cdn.snapi.dev/images/v1/b/i/biotech40.jpg)
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
![](https://cdn.snapi.dev/images/v1/e/t/etf16.jpg)
Investors flee Biotech ETFs as they Lag Bull Market
Many biotech ETFs and other funds have fallen sharply off their highs in recent months.
![](https://cdn.snapi.dev/images/v1/b/i/biotech16.jpg)
3 Charts That Suggest Now Is the Time to Buy Into Biotech
Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.